H.R. 8630: Protecting Equal Access to Thyroid Act of 2026

This bill, known as the Protecting Equal Access to Thyroid Act of 2026 (or PEAT Act), aims to amend the Public Health Service Act regarding how biologics are classified. The key points of the bill are as follows:

Purpose of the Bill

The primary objective is to ensure that a biologic product cannot be classified as a biological product purely based on the presence of a clinically inactive protein. This means that if a biologic includes a protein that does not have an active role in its effectiveness, it should not impact the product's classification status under existing regulations.

Affected Regulations

The bill proposes amendments to Section 351(i)(1) of the Public Health Service Act. The specific changes include:

• Removing any reference that would allow a biologic to be treated as a biological product solely because it contains a clinically inactive protein.
• Making a technical correction in the language of the existing statute regarding how proteins are referenced.

Implications

By clarifying the criteria for classifying biologics, the bill aims to protect access to certain products, particularly those related to thyroid treatment. It seeks to prevent unnecessary classification hurdles for biologics that contain inactive proteins, which could otherwise impede patient access and treatment options.

Summary of Changes

The bill essentially redefines how inactive proteins are treated in the context of biologics, aiming to enhance clarity and protect the equal access of patients to necessary treatments.

Relevant Companies